Table 2.

HCA response and management after cessation of OCP

	Included patients with HCA n = 78
T0: HCA diagnosis
HCA diameter at diagnosis, mm	49.0 (30.8‐86.0)
Interval between OCP cessation ‐ T0, months	0 (−0.8 to 1.0)
No. of observed HCA	78
First follow‐up (T1)
HCA diameter at first follow‐up, mm	50 (27.0‐65.0)
Interval between T0 ‐ T1, months	5.4 (4.1‐6.4)
No. of observed HCA	59
Second follow‐up (T2)
HCA diameter at second follow‐up, mm	41.0 (24.0‐61.0)
Interval between T0 ‐ T2, months	11.6 (9.9‐13.2)
No. of observed HCA	42
Total follow‐up time, y	1.1 (0.5‐2.6)
HCA subtype
H‐HCA	2 (2.6%)
I‐HCA	23 (29.5%)
β‐HCA	—
β‐IHCA	2 (2.3%)
U‐HCA	2 (2.3%)
No histopathology or subtype analysis available	49 (62.8%)
Management
Conservative	60 (76.9%)
Intervention	18 (23.1%)

HCA, hepatocellular adenoma; OCP, oral contraceptive pill. Values are given in median (interquartile range) or n (%). For HCA subtype explanation, see introduction.